Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Purchased by Barclays PLC

Barclays PLC boosted its position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 273.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 80,295 shares of the company’s stock after acquiring an additional 58,776 shares during the quarter. Barclays PLC’s holdings in Ventyx Biosciences were worth $175,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Deerfield Management Company L.P. Series C lifted its stake in shares of Ventyx Biosciences by 64.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock worth $13,466,000 after purchasing an additional 2,287,570 shares in the last quarter. Sio Capital Management LLC lifted its stake in shares of Ventyx Biosciences by 153.2% during the third quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock worth $4,299,000 after purchasing an additional 1,193,024 shares in the last quarter. Vestal Point Capital LP lifted its stake in shares of Ventyx Biosciences by 31.2% during the third quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $3,760,000 after purchasing an additional 410,000 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Ventyx Biosciences during the third quarter worth about $246,000. Finally, LMR Partners LLP acquired a new position in shares of Ventyx Biosciences during the third quarter worth about $218,000. Institutional investors and hedge funds own 97.88% of the company’s stock.

Analysts Set New Price Targets

VTYX has been the topic of a number of recent research reports. Oppenheimer restated an “outperform” rating and set a $9.00 price objective (down previously from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. HC Wainwright reiterated a “neutral” rating on shares of Ventyx Biosciences in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Insider Activity at Ventyx Biosciences

In related news, CEO Raju Mohan bought 261,752 shares of the stock in a transaction dated Monday, November 25th. The stock was bought at an average cost of $2.01 per share, with a total value of $526,121.52. Following the completion of the acquisition, the chief executive officer now owns 2,175,028 shares of the company’s stock, valued at $4,371,806.28. This trade represents a 13.68 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John Nuss sold 13,161 shares of the company’s stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $2.26, for a total value of $29,743.86. Following the transaction, the insider now directly owns 485,701 shares of the company’s stock, valued at $1,097,684.26. This trade represents a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders bought a total of 630,000 shares of company stock valued at $1,262,415 over the last three months. 18.18% of the stock is owned by insiders.

Ventyx Biosciences Stock Up 3.8 %

Shares of Ventyx Biosciences stock opened at $2.16 on Thursday. The firm has a market cap of $152.73 million, a P/E ratio of -0.92 and a beta of 0.55. Ventyx Biosciences, Inc. has a fifty-two week low of $1.67 and a fifty-two week high of $11.48. The business has a 50-day moving average price of $2.27 and a 200 day moving average price of $2.27.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.